Physician profile
Brian Kaplan
NPI 1831174242
$6,119.89
in general payments reported to CMS, 2019-2025
32 companies · $170 in 2025
The $170 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $2,386 · 2021: $262 · 2022: $246 · 2023: $710 · 2024: $743 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aesculap Implant Systems, LLC | $1,970.00 | 2020 | |
| Amgen INC. | $725.06 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $548.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $374.75 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $346.39 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $322.78 | 2019-2024 | Livalo, Seglentis |
| Astrazeneca Pharmaceuticals Lp | $302.87 | 2019-2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.82 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $172.06 | 2019-2020 | |
| Allergan, INC. | $134.46 | 2019-2020 | |
| Abbvie INC. | $124.91 | 2019-2024 | |
| Medtronic, INC. | $114.20 | 2022 | |
| Pfizer INC. | $103.11 | 2019-2023 | |
| Glaxosmithkline, LLC. | $98.99 | 2019-2023 | Shingrix, Arexvy |
| Scilex Pharmaceuticals INC. | $87.64 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $73.97 | 2019-2020 | |
| Intuitive Surgical, INC. | $66.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.83 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.77 | 2019-2022 | |
| Genentech USA, INC. | $37.82 | 2019 | |
| Bausch Health US, LLC | $30.14 | 2019 | |
| Tolmar, INC. | $28.79 | 2023-2025 | Jatenzo |
| Insmed, INC. | $21.34 | 2025 | Arikayce |
| Boston Scientific Corporation | $20.82 | 2022 | |
| Gilead Sciences, INC. | $16.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.41 | 2019 | |
| Cleerly, INC. | $16.35 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Sanofi-Aventis U.S. LLC | $15.78 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.19 | 2019 | |
| Avanos Medical | $14.82 | 2021 | |
| Antares Pharma, INC. | $14.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.